Biomarkers最新文献

{"title":"Association between the methylations of <i>RUNX3</i> in peripheral blood and lung cancer: a case-control study.","authors":"Jun Wang, Jue Wang, Jie Zhang, Haixia Gong, Jinchang Li, Yakang Song, Yuyang Huang, Boyue Ma, Wanjian Gu, Rongxi Yang","doi":"10.1080/1354750X.2024.2373714","DOIUrl":"10.1080/1354750X.2024.2373714","url":null,"abstract":"<p><strong>Background: </strong><i>RUNX3</i> is hypermethylated in multiple cancers. <i>TIMP2</i> also functions as a regulator of tumors. However, there are only very few reports on the association of methylation of <i>RUNX3</i> and <i>TIMP2</i> with lung cancer (LC) in peripheral blood.</p><p><strong>Methods: </strong>426 LC patients and 428 age- and sex-matched healthy controls were recruited. DNA methylation in blood was semi-quantitively assessed by mass spectrometry. For the association analysis, binary logistic regression analysis adjusted covariant was applied, and ORs were presented as per +10% methylation.</p><p><strong>Results: </strong>Hypermethylation of CpG_1, CpG_5 and CpG_8 in <i>RUNX3</i> was significantly associated with LC (ORs = 1.45, 1.35 and 1.35, respectively, adjusted <i>p</i> < 0.05), and even stage I LC. The association between the three <i>RUNX3</i> CpG sites and LC was enhanced by increased age (> 55 years, ORs ranged from 1.43 to 1.75, adjusted <i>p</i> < 0.05), male gender (ORs ranged from 1.47 to 1.59, adjusted <i>p</i> < 0.05) and tumor stage (stage II&III&IV, ORs ranged from 1.86 to 3.03, adjusted <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>This study suggests a significant association between blood-based <i>RUNX3</i> hypermethylation and LC, especially in elder people, in males and in LC patients with advanced stage.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts for the 18th Annual Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium","authors":"","doi":"10.1080/1354750x.2024.2376798","DOIUrl":"https://doi.org/10.1080/1354750x.2024.2376798","url":null,"abstract":"Published in Biomarkers (Just accepted, 2024)","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141588501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>CCDC12</i> gene methylation in peripheral blood as a potential biomarker for breast cancer detection.","authors":"Jingjing Liu, Yunhui Qu, Yutong Zhao, Feifei Liang, Longtao Ji, Zhi Wang, Jinyu Li, Zishan Zang, Haixia Huang, Jie Zhang, Wanjian Gu, Liping Dai, Rongxi Yang","doi":"10.1080/1354750X.2024.2358302","DOIUrl":"10.1080/1354750X.2024.2358302","url":null,"abstract":"<p><strong>Background: </strong>Aberrant DNA methylation has been identified as biomarkers for breast cancer detection. Coiled-coil domain containing 12 gene (<i>CCDC12</i>) implicated in tumorigenesis. This study aims to investigate the potential of blood-based <i>CCDC12</i> methylation for breast cancer detection.</p><p><strong>Methods: </strong>DNA methylation level of CpG sites (Cytosine-phosphate Guanine dinucleotides) in <i>CCDC12</i> gene was measured by mass spectrometry in 255 breast cancer patients, 155 patients with benign breast nodules and 302 healthy controls. The association between <i>CCDC12</i> methylation and breast cancer risk was evaluated by logistic regression and receiver operating characteristic curve analysis.</p><p><strong>Results: </strong>A total of eleven CpG sites were analyzed. The <i>CCDC12</i> methylation levels were higher in breast cancer patients. Compared to the lowest tertile of methylation level in CpG_6,7, CpG_10 and CpG_11, the highest quartile was associated with 82, 91 and 95% increased breast cancer risk, respectively. The <i>CCDC12</i> methylation levels were associated with estrogen receptor (ER) and human epidermal growth factor 2 (HER2) status. In ER-negative and HER2-positive (ER-/HER2+) breast cancer subtype, the combination of four sites CpG_2, CpG_5, CpG_6,7 and CpG_11 methylation levels could distinguish ER-/HER2+ breast cancer from the controls (AUC = 0.727).</p><p><strong>Conclusion: </strong>The hypermethylation levels of <i>CCDC12</i> in peripheral blood could be used for breast cancer detection.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher expression of SALL4-A isoform is correlated with worse outcomes and progression of the disease in subtype of testicular germ cell tumours.","authors":"Niknam Lakpour, Roya Ghods, Maryam Abolhasani, Leili Saeednejad Zanjani, Kioomars Saliminejad, Elham Kalantari, Sima Saki, Mohammad Mehdi Ranjbar, Leila Balay-Goli, Mohammad Reza Sadeghi, Zahra Madjd","doi":"10.1080/1354750X.2024.2361796","DOIUrl":"10.1080/1354750X.2024.2361796","url":null,"abstract":"<p><strong>Background: </strong>The transcription factor SALL4 is associated with embryonic pluripotency and has proposed as a novel immunohistochemistry (IHC) marker for diagnosing germ cell tumours. SALL4 comprises three isoforms, and SALL4-A being the full-length isoform. Studying its isoforms could revolutionize testicular cancer prognosis and subtype differentiation.</p><p><strong>Methods: </strong>The expression and clinical significance of isoform 'A' of SALL4 was evaluated in 124 testicular germ cell tumours (TGCTs) subtypes, adjacent 67 normal tissues and 22 benign tumours, using immunohistochemistry on tissue microarrays (TMA).</p><p><strong>Results: </strong>A statistically significant higher expression of nuclear and cytoplasmic SALL4-A was detected in TGCTs histological subtypes and benign tumours compared to the normal tissues. Seminoma and yolk sac tumours had the highest nuclear and cytoplasmic expression of SALL4-A. A significant correlation was detected between the higher nuclear expression of SALL4-A and increased pT stages (<i>P</i> = 0.026) in seminomas. Whereas in embryonal carcinomas, cytoplasmic expression of SALL4-A was associated with the tumour recurrence (<i>P</i> = 0.04) and invasion of the epididymis (<i>P</i> = 0.011).</p><p><strong>Conclusions: </strong>SALL4-A isoform expression in the cytoplasm and nucleus of TGCTs may be associated with histological differentiation. In the seminoma subtype of TGCTs, higher expression of SALL4-A may be used as a predictive indicator of poorer outcomes and prognosis.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141159973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyponatremia in the emergency department: an overview of diagnostic and therapeutic approach.","authors":"Charlotte Wernicke, Ulrike Bachmann, Knut Mai","doi":"10.1080/1354750X.2024.2361074","DOIUrl":"10.1080/1354750X.2024.2361074","url":null,"abstract":"<p><strong>Introduction: </strong>Hyponatremia, defined as a serum sodium concentration <135 mmol/l, is a frequent electrolyte disorder in patients presenting to an emergency department (ED). In this context, appropriate diagnostic and therapeutic management is rarely performed and challenging due to complex pathophysiologic mechanisms and a variety of underlying diseases.</p><p><strong>Objective: </strong>To implement a feasible pathway of central diagnostic and therapeutic steps in the setting of an ED.</p><p><strong>Methods: </strong>We conducted a narrative review of the literature, considering current practice guidelines on diagnosis and treatment of hyponatremia. Underlying pathophysiologic mechanisms and management of adverse treatment effects are outlined. We also report four cases observed in our ED.</p><p><strong>Results: </strong>Symptoms associated with hyponatremia may appear unspecific and range from mild cognitive deficits to seizures and coma. The severity of hyponatremia-induced neurological manifestation and the risk of poor outcome is mainly driven by the rapidity of serum sodium decrease. Therefore, emergency treatment of hyponatremia should be guided by symptom severity and the assumed onset of hyponatremia development, distinguishing acute (<48 hours) versus chronic hyponatremia (>48 hours).</p><p><strong>Conclusions: </strong>Especially in moderately or severely symptomatic patients presenting to an ED, the application of a standard management approach appears to be critical to improve overall outcome. Furthermore, an adequate work-up in the ED enables further diagnostic and therapeutic evaluation during hospitalization.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic prediction of oxidative stress related hematological biomarkers in locally advanced cervical cancer patients undergoing chemoradiotherapy.","authors":"Gang Wu, Mengxuan Gu, Jiahao Zhu, Ruike Gu, Bo Yang, Shengjun Ji, Yutian Zhao, Ke Gu","doi":"10.1080/1354750X.2024.2358300","DOIUrl":"10.1080/1354750X.2024.2358300","url":null,"abstract":"<p><strong>Objective: </strong>This investigation aimed to develop and validate a novel oxidative stress score for prognostic prediction in locally advanced cervical cancer (LACC) patients receiving chemoradiotherapy.</p><p><strong>Methods: </strong>A total of 301 LACC patients were enrolled and randomly divided into a training and a validation set. The association between oxidative stress parameters and prognosis was analyzed for oxidative stress score (OSS) establishment. A Cox regression model was conducted for overall survival (OS) and progression-free survival (PFS). A nomogram prediction model was developed using independent prognostic factors from the training set and validated in the validation set.</p><p><strong>Results: </strong>A novel OSS was established with four oxidative stress parameters, including albumin, total bilirubin, blood urea nitrogen, and lactate dehydrogenase. Multivariate regression analysis identified OSS as an independent prognostic factor for OS (<i>p</i> = 0.001) and PFS (<i>p</i> < 0.001). A predictive nomogram based on the OSS was established and validated. The C-indexes of the nomogram in the training set were 0.772 for OS and 0.781 for PFS, while in the validation set the C-indexes were 0.642 for OS and 0.621 for PFS.</p><p><strong>Conclusion: </strong>This study confirmed that preoperative OSS could serve as a useful independent prognostic factor in LACC patients who received CCRT.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of switching from cigarette smoking to tobacco heating system use on biomarkers of potential harm in a randomized trial.","authors":"S Michael Ansari, Paul S Hession, Morgane David, Nicolas Blanc, Guillaume de La Bourdonnaye, Sandrine Pouly, Christelle Haziza","doi":"10.1080/1354750X.2024.2358318","DOIUrl":"10.1080/1354750X.2024.2358318","url":null,"abstract":"<p><strong>Background: </strong>Smoking cessation reduces the risk of developing smoking-related diseases. Although smoking prevalence has declined, many continue smoking cigarettes. Switching completely to smoke-free alternatives like the Tobacco Heating System (THS) 2.2-a heated tobacco product for which there is evidence demonstrating significantly reduced formation and exposure to harmful chemicals compared to cigarettes-has the potential to reduce the harm caused by continuing to smoke cigarettes.</p><p><strong>Methods: </strong>We conducted a 6-month clinical study (NCT02396381) with a 6-month extension (NCT02649556), initially randomizing 984 adult smokers to continue smoking or switch to THS (non-mentholated), of which 672 continued into the extension study. Endpoints were evaluated at baseline and at 3, 6, and 12 months. We longitudinally assessed biomarkers of potential harm (BoPHs) known to be reversible upon smoking cessation as indicators of pathways involved in the pathogenesis of cardiovascular or respiratory diseases and carcinogenicity. The need to cough and safety profile were also assessed. Impact on eight key BoPHs was used as a proxy to evaluate harm reduction potential.</p><p><strong>Results: </strong>At 12 months, comparison of BoPH levels between the predominant THS use and cigarette smoking groups showed a positive effect in favor of switching, partially or in full, to THS.</p><p><strong>Conclusion: </strong>These results provide additional evidence of the harm reduction potential of THS for smokers who would otherwise continue smoking, but they need to be verified in long-term confirmatory studies.</p><p><strong>Clinical trial registration: </strong>Clinicaltrials.gov Identifier: NCT0264955. Date of registration: January 7, 2016 https://clinicaltrials.gov/ct2/show/NCT02649556.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141157512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing the accuracy of a four serum microRNA panel for the detection of primary bladder cancer: a discovery and validation study.","authors":"Chong Lu, Shengjie Lin, Zhenyu Wen, Chen Sun, Zhenjian Ge, Wenkang Chen, Yingqi Li, Pengwu Zhang, Yutong Wu, Wuping Wang, Siwei Chen, Huimei Zhou, Xutai Li, Hang Li, Lingzhi Tao, Yimin Hu, Zhengping Zhao, Zebo Chen, Xionghui Wu, Yongqing Lai","doi":"10.1080/1354750X.2024.2358312","DOIUrl":"10.1080/1354750X.2024.2358312","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BC) is one of the ten most common cancers worldwide with late detection and early age of diagnosis. There is abundant evidence that early detection and timely intervention can lead to a better prognosis of BC. Substantial evidence has indicated that microRNAs (miRNAs) are specific to different tumour types and are remarkably stable, indicating that serum miRNAs may serve as potential cancer diagnostic markers. This study aimed to identify suitable serum miRNAs to create a panel that can be used to diagnose primary BC.</p><p><strong>Methods: </strong>In this study, 18 miRNAs that were differentially expressed in BC were obtained from the PubMed or Gene Expression Omnibus database. Then, 18 BC-related-miRNAs were verified in screening and validation sets created using 56 (28 primary BC vs. 28 NCs) and 168 (84 primary BC vs. 84 NCs) serum samples, respectively. Quantitative reverse transcription-PCR (qRT-PCR) was performed to verify the identity of the differential miRNAs. A multi-miRNA panel with superior diagnostic performance was constructed. TCGA and KEGG databases were used to conduct the survival analysis and bioinformatics analysis, respectively.</p><p><strong>Results: </strong>Six serum miRNAs (miR-221-5p, miR-181a-5p, miR-98-5p, miR-15a-5p, miR-222-3p, and miR-197-3p) were significantly aberrantly expressed in the BC patients, while four miRNAs from among them (miR-221-5p, miR-181a-5p, miR-15a-5p, miR-222-3p) were assembled into a panel that showed high diagnostic value (AUC = 0.875, 95% CI: 0.815 - 0.921; sensitivity: 82.14%; and specificity: 85.71%) based on the logistic regression analysis. The survival analysis showed that miR-181a-5p was closely associated with BC prognosis (Log-rank <i>p</i>-value < 0.05).</p><p><strong>Conclusion: </strong>The combination of the four miRNAs (miR-221-5p, miR-181a-5p, miR-15a-5p and miR-222-3p) may be a novel non-invasive serological biomarker for BC screening.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of ion channel-related genes as diagnostic markers and potential therapeutic targets for osteoarthritis through bioinformatics and machine learning-based approaches.","authors":"Liu Yongming, Xiong Yizhe, Qian Zhikai, Wang Yupeng, Wang Xiang, Yin Mengyuan, Du Guoqing, Zhan Hongsheng","doi":"10.1080/1354750X.2024.2358316","DOIUrl":"10.1080/1354750X.2024.2358316","url":null,"abstract":"<p><strong>Background: </strong>Osteoarthritis (OA) is a debilitating joint disorder characterized by the progressive degeneration of articular cartilage. Although the role of ion channels in OA pathogenesis is increasingly recognized, diagnostic markers and targeted therapies remain limited.</p><p><strong>Methods: </strong>In this study, we analyzed the GSE48556 dataset to identify differentially expressed ion channel-related genes (DEGs) in OA and normal controls. We employed machine learning algorithms, least absolute shrinkage and selection operator(LASSO), and support vector machine recursive feature elimination(SVM-RFE) to select potential diagnostic markers. Then the gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were performed to explore the potential diagnostic markers' involvement in biological pathways. Finally, weighted gene co-expression network analysis (WGCNA) was used to identify key genes associated with OA.</p><p><strong>Results: </strong>We identified a total of 47 DEGs, with the majority involved in transient receptor potential (TRP) pathways. Seven genes (CHRNA4, GABRE, HTR3B, KCNG2, KCNJ2, LRRC8C, and TRPM5) were identified as the best characteristic genes for distinguishing OA from healthy samples. We performed clustering analysis and identified two distinct subtypes of OA, C1, and C2, with differential gene expression and immune cell infiltration profiles. Then we identified three key genes (PPP1R3D, ZNF101, and LOC651309) associated with OA. We constructed a prediction model using these genes and validated it using the GSE46750 dataset, demonstrating reasonable accuracy and specificity.</p><p><strong>Conclusions: </strong>Our findings provide novel insights into the role of ion channel-related genes in OA pathogenesis and offer potential diagnostic markers and therapeutic targets for the treatment of OA.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing gastrointestinal cancer diagnostics: a systematic review and meta-analysis of circulating microRNA-1246 as a non-invasive biomarker.","authors":"Amir Hossein Aalami, Ali Shahriari, Mohammad Mazaheri, Farnoosh Aalami, Amirhossein Sahebkar","doi":"10.1080/1354750X.2024.2350714","DOIUrl":"10.1080/1354750X.2024.2350714","url":null,"abstract":"<p><strong>Background: </strong>Despite numerous reports on the alterations of microRNA-1246 (miR-1246) expression level in digestive system cancers, its role in gastrointestinal cancers (GICs) remains unclear. This meta-analysis aimed to assess the diagnostic potential of circulating miR-1246 in GICs.</p><p><strong>Methods: </strong>Meta-disc version 1.4 and Comprehensive Meta-Analysis (CMA) version 3.7 software were used to calculate pooled sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR), area under the curve (AUC), Q*index and summary receiver-operating characteristic (SROC). Subgroup analyses were conducted for cancer type, sample type and geographical region. Publication bias was assessed using Begg's and Egger's tests.</p><p><strong>Results: </strong>A total of 14 articles involving 18 studies and 1526 participants (972 cases and 554 controls) were included. The diagnostic accuracy of miRNA-1246 in GICs was as follows: pooled sensitivity: 0.81 (95% CI: 0.79 - 0.83), specificity: 0.74 (95% CI: 0.71 - 0.77), PLR: 3.315 (95% CI: 2.33 - 4.72), NLR: 0.221 (95% CI: 0.153 - 0.319), DOR: 16.87 (95% CI: 9.45 - 30.09), AUC: 0.891, and Q*-index: 0.807. No publication bias was found based on Begg's (<i>p</i> = 0.172) and Egger's (<i>p</i> = 0.113) tests.</p><p><strong>Conclusion: </strong>Circulating miR-1246 shows promise as a non-invasive biomarker for early detection of GICs.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140849394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}